Pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, Vaxzevria, following revelations of a rare and dangerous side effect. The decision comes after the company acknowledged in court documents that the vaccine can cause Thrombosis Thrombocytopenia Syndrome (TTS), prompting concerns over its safety.
AstraZeneca revealed that the vaccine is no longer being manufactured or supplied, citing commercial reasons for the withdrawal. However, the timing coincides with increasing scrutiny over the vaccine’s potential to induce TTS, a condition characterized by blood clots and low blood platelet counts.
The vaccine’s marketing authorisation has been voluntarily withdrawn in the European Union, rendering it unauthorized for use. Similar applications for withdrawal are expected in other previously approved countries, including the UK.
The admission of the vaccine’s risk factors has sparked legal proceedings, with AstraZeneca facing lawsuits from over 50 alleged victims and bereaved relatives. The company’s acknowledgment of the link between the vaccine and TTS has raised public concern and prompted calls for further investigation.
In response to the controversy, AstraZeneca reiterated its pride in the vaccine’s contribution to combating the pandemic, citing estimates of millions of lives saved and billions of doses supplied globally. However, the company’s efforts have been overshadowed by safety concerns and legal challenges.
Read Now:Cabin Crew Protests Lead to Flight Cancellations and Delays at Air India Express
